HHS awards $323M contract to LabCorp for COVID-19 lab testing services through April 2025

Contract Overview

Contract Amount: $32,283,750 ($32.3M)

Contractor: Laboratory Corporation of America

Awarding Agency: Department of Health and Human Services

Start Date: 2022-05-16

End Date: 2025-04-22

Contract Duration: 1,072 days

Daily Burn Rate: $30.1K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 23

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: COVID-19 LAB TESTING

Place of Performance

Location: BURLINGTON, ALAMANCE County, NORTH CAROLINA, 27215

State: North Carolina Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $32.3 million to LABORATORY CORPORATION OF AMERICA for work described as: COVID-19 LAB TESTING Key points: 1. Contract value represents significant investment in ongoing public health surveillance. 2. LabCorp's established infrastructure likely supports efficient service delivery. 3. Fixed-price contract offers cost certainty for the government. 4. Long-term nature of the contract suggests sustained demand for testing. 5. Performance period extends beyond immediate pandemic response, indicating long-term strategy. 6. The contract is a definitive contract, suggesting a clear scope of work.

Value Assessment

Rating: good

The contract value of $322.8 million over approximately two years for COVID-19 lab testing appears reasonable given the scale of public health needs. Benchmarking against similar large-scale testing contracts is difficult without more specific service details, but LabCorp is a major provider in this space. The firm fixed-price structure provides cost predictability. The number of offers (23) suggests a competitive process that likely contributed to a fair price.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, with 23 offers received. This indicates a robust bidding process where multiple qualified vendors had the opportunity to compete. A high number of bidders generally suggests a healthy market and can lead to more competitive pricing as vendors vie for the award.

Taxpayer Impact: The extensive competition for this contract is beneficial for taxpayers, as it likely drove down costs and ensured the government secured services at a favorable price point.

Public Impact

The primary beneficiaries are the American public, who gain access to essential COVID-19 laboratory testing services. Services delivered include diagnostic testing crucial for public health monitoring and individual health management. The geographic impact is national, supporting the Centers for Disease Control and Prevention's (CDC) nationwide surveillance efforts. Workforce implications include potential job creation or retention within LabCorp's laboratory operations and support staff.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for over-reliance on a single large contractor for critical public health services.
Need for robust performance monitoring to ensure quality and timeliness of testing results.

Positive Signals

Award to a well-established provider with existing infrastructure and expertise.
Firm fixed-price contract provides budget certainty.
Full and open competition indicates a competitive market and likely fair pricing.
Long contract duration suggests sustained commitment to public health needs.

Sector Analysis

The healthcare sector, specifically clinical laboratory services, is a critical component of public health infrastructure. This contract falls within the broader market for diagnostic testing, which has seen significant growth and evolution, particularly due to the COVID-19 pandemic. LabCorp is a major player in this market, competing with other large national laboratories and specialized testing facilities. The government's spending in this area reflects a commitment to maintaining robust testing capabilities.

Small Business Impact

This contract does not appear to have a small business set-aside component, as indicated by 'sb': false. While LabCorp is a large business, there may be opportunities for small businesses to participate as subcontractors to LabCorp, depending on the specific service requirements and LabCorp's subcontracting strategy. Further analysis would be needed to determine the extent of small business involvement.

Oversight & Accountability

Oversight will likely be managed by the Centers for Disease Control and Prevention (CDC) contracting officers and program managers. Accountability measures are typically embedded in contract terms, including performance standards, reporting requirements, and potential remedies for non-performance. Transparency is facilitated through contract databases like FPDS. Inspector General jurisdiction would apply in cases of suspected fraud, waste, or abuse.

Related Government Programs

COVID-19 Testing Programs
Public Health Surveillance
Diagnostic Laboratory Services
National Health Security Contracts

Risk Flags

Performance Risk
Contractor Dependency
Turnaround Time Variability

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $32.3 million to LABORATORY CORPORATION OF AMERICA. COVID-19 LAB TESTING

Who is the contractor on this award?

The obligated recipient is LABORATORY CORPORATION OF AMERICA.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Centers for Disease Control and Prevention).

What is the total obligated amount?

The obligated amount is $32.3 million.

What is the period of performance?

Start: 2022-05-16. End: 2025-04-22.

What is LabCorp's track record with government contracts, particularly for public health services?

Laboratory Corporation of America Holdings (LabCorp) has a significant history of performing contracts for various U.S. government agencies, including the Department of Health and Human Services (HHS), Department of Defense (DoD), and Veterans Affairs (VA). Their experience spans a wide range of laboratory services, including clinical diagnostics, research support, and public health testing. Notably, LabCorp has been a key provider of COVID-19 testing services throughout the pandemic, often receiving substantial government funding for these efforts. Their established infrastructure, national reach, and experience with large-scale testing initiatives suggest a strong capability to fulfill the requirements of this contract. However, as with any large contractor, past performance reviews and specific contract adherence should be continuously monitored.

How does the value of this contract compare to similar federal spending on COVID-19 lab testing?

The $322.8 million awarded to LabCorp for COVID-19 lab testing is substantial and aligns with the significant federal investment in pandemic response and ongoing public health surveillance. During the height of the pandemic, federal agencies, particularly HHS and the CDC, awarded billions of dollars for testing, vaccine development, and related services. This specific contract, awarded in May 2022 and running through April 2025, reflects a sustained need for testing beyond the initial emergency phase, likely for monitoring purposes and supporting public health strategies. While direct comparisons are complex due to varying scopes, durations, and specific services, this award is consistent with the scale of federal commitment to maintaining COVID-19 testing capabilities.

What are the primary risks associated with this contract, and how are they mitigated?

Key risks for this contract include potential performance issues (e.g., delays in testing turnaround times, quality control failures), over-reliance on a single large contractor, and the possibility of cost overruns if the scope significantly expands beyond initial projections, despite the firm fixed-price nature. Mitigation strategies likely include robust performance monitoring by the CDC, clear service level agreements (SLAs) within the contract, regular quality assurance checks, and contingency planning. The competitive award process itself helps mitigate the risk of selecting an underqualified vendor. Furthermore, the government may retain options for additional testing providers or surge capacity if needed, though this contract appears to be a primary vehicle.

How effective has LabCorp been in delivering similar public health testing services in the past?

LabCorp has generally demonstrated effectiveness in delivering large-scale public health testing services, particularly in response to the COVID-19 pandemic. They were one of the primary commercial laboratories scaling up PCR and antigen testing capacity nationwide. Their ability to process millions of tests and integrate with public health reporting systems has been crucial. However, like many high-volume testing providers during peak demand, they faced challenges related to turnaround times and capacity constraints at various points. The CDC's ongoing oversight and performance metrics within this new contract will be critical for ensuring continued effectiveness and addressing any emerging issues.

What are the historical spending patterns for COVID-19 lab testing by the CDC and HHS?

Historical spending by the CDC and HHS on COVID-19 lab testing has been extensive, particularly from 2020 through 2022. Billions of dollars were allocated through various contract vehicles, grants, and cooperative agreements to support diagnostic testing, genomic surveillance, and research. Spending patterns evolved from initial emergency procurements for surge capacity to more sustained contracts for ongoing monitoring and public health infrastructure. This $323 million award to LabCorp fits within the latter category, reflecting a strategic, longer-term investment in maintaining essential testing capabilities as part of the nation's public health preparedness.

Industry Classification

NAICS: Health Care and Social Assistance › Medical and Diagnostic Laboratories › Medical Laboratories

Product/Service Code: MEDICAL SERVICES › LABORATORY TESTING SERVICES

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 75D301-22-Q-74748

Offers Received: 23

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Bode Cellmark Forensics Inc.

Address: 231 MAPLE AVE, BURLINGTON, NC, 27215

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $91,693,500

Exercised Options: $91,693,500

Current Obligation: $32,283,750

Actual Outlays: $32,283,750

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline